Johnson & Johnson reported its fourth-quarter earnings for 2024, surpassing Wall Street estimates with adjusted earnings per share of $2.04 and revenue of $22.52 billion, compared to estimates of $1.99 and $22.43 billion, respectively. The company's performance was driven by strong sales of cancer-treating drugs, with Darzalex and Erleada showing significant year-over-year increases of over 20%. However, sales of the psoriasis drug Stelara declined by 14.7% due to the introduction of generics in Canada and Europe. Johnson & Johnson also announced a $14.6 billion acquisition of Intra-Cellular Therapies, adding Caplyta, a mental health disorder drug with a patent until 2040, to its portfolio. Despite the earnings beat, the company's stock fell by 1.6% in premarket trading, reflecting concerns over future sales guidance and ongoing challenges such as the talc lawsuit and competition from generics. The company reported a net income of $4.8 billion for the quarter.